TNX-1300 Emerging Drug Insight

“TNX-1300 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about TNX-1300 for Cocaine Intoxication in the 7MM. A detailed picture of the TNX-1300 for Cocaine Intoxication in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the TNX-1300 for Cocaine Intoxication. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TNX-1300 market forecast, analysis for Cocaine Intoxication in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Cocaine Intoxication.

Drug Summary

TNX-1300, which Tonix Pharmaceutical is developing, is a recombinant protein enzyme produced through recombinant DNA technology in a non-disease-producing strain of E. coli bacteria. Cocaine Esterase (CocE) was identified in bacteria (Rhodococcus) that use cocaine as their sole source of carbon and nitrogen and grow in the soil surrounding coca plants. The gene encoding CocE was identified, and the protein was extensively characterized. CocE catalyzes the breakdown of cocaine into metabolite ecgonine methyl ester and benzoic acid.

Wild-type CocE is unstable at body temperature, so targeted mutations were introduced in the CocE gene and resulted in the double-mutant CocE, which is active for approximately 6 h at body temperature.

In a Phase II study, TNX-1300 at 100 mg or 200 mg IV doses were well tolerated and interrupted cocaine effects after cocaine 50 mg IV challenge (Tonix Pharmaceuticals, 2021). TNX-1300 was well tolerated, with the most frequently reported adverse events being gastrointestinal disorders (including dry mouth, nausea), nervous systems disorders (including headache, dizziness), and skin and subcutaneous tissue disorders (including hyperhidrosis, dermatitis). By targeting the cause of cocaine intoxication rather than the symptoms like other medicines in emergency usage, TNX-1300 may offer significant advantages to the current standard of care for cocaine overdose.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the TNX-1300 description, mechanism of action, dosage and administration, research and development activities in Cocaine Intoxication.
•  Elaborated details on TNX-1300 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the TNX-1300 research and development activity in Cocaine Intoxication details across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around TNX-1300.
•  The report contains forecasted sales of TNX-1300 for Cocaine Intoxication till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Cocaine Intoxication.
•  The report also features the SWOT analysis with analyst views for TNX-1300 in Cocaine Intoxication.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TNX-1300 Analytical Perspective by DelveInsight

• In-depth TNX-1300 Market Assessment

This report provides a detailed market assessment of TNX-1300 in Cocaine Intoxication in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data for TNX-1300.

•  TNX-1300 Clinical Assessment

The report provides the clinical trials information of TNX-1300 for Cocaine Intoxication covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Cocaine Intoxication is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TNX-1300 dominance.
•  Other emerging products for Cocaine Intoxication are expected to give tough market competition to TNX-1300 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TNX-1300 in Cocaine Intoxication.
•  Our in-depth analysis of the forecasted sales data of TNX-1300 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TNX-1300 in Cocaine Intoxication.

Key Questions

•  What is the product type, route of administration and mechanism of action of TNX-1300?
•  What is the clinical trial status of the study related to TNX-1300 in Cocaine Intoxication and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TNX-1300 development?
•  What are the key designations that have been granted to TNX-1300 for Cocaine Intoxication?
•  What is the forecasted market scenario of TNX-1300 for Cocaine Intoxication?
•  What are the forecasted sales of TNX-1300 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Cocaine Intoxication and how are they giving competition to TNX-1300 for Cocaine Intoxication?
•  Which are the late-stage emerging therapies under development for the treatment of Cocaine Intoxication?